touchNEUROLOGY had the pleasure of meeting with Amy Gelfand (University of California, San Francisco, CA, USA) to discuss what is known about the impact of preventative migraine medication on the COVID-19 vaccine.
The session ‘Vaccines and Their Impact on Migraine Treatment’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- What is the influence of NSAIDs on the immune response to vaccination? (0:17)
- Does acute migraine treatment impair the efficacy, or impact the safety, of the COVID-19 vaccine? (1:08)
- What is known about the impact of preventative migraine medication on the COVID-19 vaccine? (1:36)
- Does the COVID-19 vaccine adversely impact the efficacy of migraine treatments? (2:49)
- Should migraine patients be concerned about the risk of thrombosis after adenovirus COVID-19 vaccines? (3:20)
Disclosures: Amy Gelfand has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Jessica Ailani, EAN 2021: Phase 3b CONQUER Trial Results
It was a great pleasure to meet with Jessica Ailani (MedStar Georgetown, Georgetown University Hospital, Pasquerilla Healthcare Center, Washington, WA, USA) to discuss the impact of galcanezumab on migraine care in the phase 3b CONQUER trial. The abstract entitled: ‘Total pain burden in patients with treatment-resistant migraine: effects of galcanezumab in the CONQUER Phase 3b […]
Michael Marmura, AHS 2021: Intranasal Ketamine for the Treatment of Refractory Headache
touchNEUROLOGY met with Michael Marmura (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss his study investigating intranasal ketamine for the treatment of refractory headache. The abstract ‘Intranasal Ketamine for Refractory Headache’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021. Questions: What is the rationale […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!